WordNet

an antiviral protein produced by cells that have been invaded by a virus; inhibits replication of the virus

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Association of immune response parameters with virological response in hepatitis C virus patients treated with pegylated consensus interferon.

Ding Y, Zhang H, Chen H, Li X, Liu C, Li Q, Niu J.
International journal of clinical pharmacology and therapeutics.Int J Clin Pharmacol Ther.2016 Mar;54(3):163-71. doi: 10.5414/CP202439.
BACKGROUND: A new, potent, long lasting recombinant interferon variant (pegylated consensus interferon, PEGCIFN) was expressed by Escherichia coli. The aim of this study was to test safety and antiviral activity of the new type of interferon in adults with hepatitis C virus (HCV) infection and to de
PMID 26754309

Small Molecule Agonists for the Type I Interferon Receptor: An In Silico Approach.

Wei L1,2,3, Bello AM1,2,3, Majchrzak-Kita B2, Salum N1,4, Lewis MM1,2, Kotra LP1,2,3, Fish EN2,5.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.J Interferon Cytokine Res.2016 Mar;36(3):180-91. doi: 10.1089/jir.2015.0123. Epub 2015 Dec 24.
Type I interferons (IFNs) exhibit broad-spectrum antiviral activity, with potential utility against emerging acute virus infections that pose a threat to global health. Recombinant IFN-αs that have been approved for clinical use require cold storage and are administered through intramuscular or sub
PMID 26700737

Development of a Hyperglycosylated IFN Alfacon-1 (CIFN): Toward Bimonthly or Monthly Dosing for Antiviral Therapies.

Taylor JS1, Zhang Q1, Julander JG2, Stoycheva AD1, Tan H1, Moy CV1, Chanda S1, Symons JA1, Beigelman LN1, Blatt LM1, Hong J1.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.J Interferon Cytokine Res.2015 Aug;35(8):621-33. doi: 10.1089/jir.2014.0138. Epub 2015 Apr 13.
Type 1 interferons (IFNs) have been shown to be efficacious against hepatitis C virus (HCV), hepatitis B virus (HBV), and some cancers with a significant drawback of short drug exposure. We have significantly improved the pharmacokinetic (PK) of consensus interferon (CIFN) by glycoengineering. We ge
PMID 25866898